Not sure that for patients waiting around for an hour with the current testing regime is a big deal. I have done it twice and would prefer to having to return to the testing centre the next day. I thought a potentially significant advantage of CU6's technology is that it remains effective significantly longer so a more centralised manufacturing and distribution model is possible as compared with, say Telix's product.
Ann: First patient treated in theranostic prostate cancer trial, page-13
Add CU6 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$4.98 |
Change
-0.220(4.23%) |
Mkt cap ! $1.551B | |||
| Open | High | Low | Value | Volume |
| $5.10 | $5.20 | $4.92 | $4.336M | 862.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 11336 | $4.96 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $4.98 | 207 | 1 |
View Market Depth
| Last trade - 16.10pm 05/07/2024 (20 minute delay) ? |
| CU6 (ASX) Chart |